Sign In
Buy CBIO
$17.98
+0.98 (+5.73%)
At Close: Jun 03, 2026
uniQure (QURE) Receives a Rating Update from a Top Analyst
03:26pm, Tuesday, 03'rd Mar 2020
Chardan Capital analyst
Gbola Amusa
reiterated a
Buy
rating on uniQure (
QURE
–
Research Report
) today and set a price target of
$105.00
. The company’s shares closed last Monday at $56.50.
Accor
C16 Biosciences Company Profile: Valuation & Investors | PitchBook
07:58pm, Monday, 02'nd Mar 2020
Information on valuation, funding, cap tables, investors, and executives for C16 Biosciences. Use the PitchBook Platform to explore the full profile.
Critical Survey: Pulse Biosciences (NASDAQ:PLSE) versus RA Medical Systems (NASDAQ:RMED)
07:48am, Saturday, 29'th Feb 2020
Pulse Biosciences (NASDAQ:PLSE) and RA Medical Systems (NYSE:RMED) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength o
Oppenheimer Maintains Their Buy Rating on Athenex (ATNX)
07:34pm, Thursday, 27'th Feb 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Athenex (ATNX) today and set a price target of $23.00. The company's shares closed last
Oppenheimer Maintains Their Buy Rating on Athenex (ATNX)
07:33pm, Thursday, 27'th Feb 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Athenex (ATNX – Research Report) today and set a price target
Wall Street Analysts Are Bullish on Top Healthcare Picks
08:43am, Thursday, 27'th Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novavax (NVAX) and Intercept Pharma (ICPT) with bullish
Catalyst Biosciences to Present at the Cowen Healthcare Conference
01:00pm, Monday, 24'th Feb 2020
Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Cowen Healthcare C
Oppenheimer Reaffirms Their Buy Rating on Vericel (VCEL)
11:19pm, Sunday, 23'rd Feb 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Vericel (VCEL – Research Report) today and set a price target
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update
09:05pm, Thursday, 20'th Feb 2020
Presented positive clinical and pre-clinical data from its MarzAA and DalcA hemophilia programs Announced a global license and collaboration agreement with Biogen to develop.
Analysts Offer Insights on Healthcare Companies: Molecular Templates (MTEM), Atricure (ATRC) and Fate Therapeutics (FATE)
10:06pm, Wednesday, 19'th Feb 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Templates (MTEM), Atricure (ATRC) and Fate
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Templates
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
09:05pm, Tuesday, 18'th Feb 2020
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, (the Company), today announced the closing o
NTAP, AEG among premarket losers
02:17pm, Thursday, 13'th Feb 2020
XBiotech (NASDAQ:XBIT) -26% on preliminary results of tender offer.Akorn (NASDAQ:AKRX) -20% after extending standstill period.Catalyst Biosciences (NASDAQ:CBIO) -18% on equity offering.Nu Skin En
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
02:15pm, Thursday, 13'th Feb 2020
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, (the Company), today announced the pricing
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
01:05pm, Thursday, 13'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (N
